2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA)Gregory Y H Lip, Ronald Jardine, Francisco Marı́n et al.|EP Europace|2018Cited by 279
The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery diseaseThomas O. Bergmeijer, Paul A. Gurbel, Udaya S. Tantry et al.|Thrombosis and Haemostasis|2014Cited by 32
Coronary Computed Tomography Angiography in Prediction of First Coronary EventsGöran Bergström, Tomas Jernberg, Gunnar Engström et al.|JAMA|2025Cited by 27
Clopidogrel metaboliser status based on point-of-care CYP2C19 genetic testing in patients with coronary artery diseaseStefan James, David Erlinge, Suman Duvvuru et al.|Thrombosis and Haemostasis|2014Cited by 21
TCT-900 Comparison of Drug-Coated Balloons and The Bioadaptor in Treatment of De Novo Coronary Lesions: A 2-Year Nationwide Analysis from SWEDEHEARTDavid Erlinge, Moman A. Mohammad, Sacharias von Koch et al.|Journal of the American College of Cardiology|2025Cited by 0